Sentences with phrase «financial results at»

Move will host a conference call to discuss the second quarter 2013 financial results at 2:00 p.m. Pacific Daylight Time (5:00 p.m. Eastern Daylight Time) on the same day.

Financial results at six of the most profitable New York — based firms showed single - digit growth and even slighter profitability gains in 2011, according to The American Lawyer's reporting.

Berwin Leighton Paisner (BLP) saw revenue fall by just under 2 % in 2015 - 16 to # 254m, down from # 259m in 2014 - 15, with the firm announcing its financial results at the same time as confirming that it is delaying its salary reviews in the wake of Brexit.

A bond's price may decline because of unexpected news or financial results at the issuing company, or within the company's industry.

IAC released its Q4 2014 financial results at the beginning of February, reporting a 9 % decline in profit for the fourth quarter from last year.

Levine argues that activists pressure companies to focus on short - term financial results at the expense of long - term investments in company growth.

Rockwell Collins to issue second quarter fiscal year 2018 financial results on April 27 - Apr 6, 2018 - Rockwell Collins (NYSE: COL) will issue a press release reporting its second quarter fiscal year 2018 financial results at approximately 6:30 a.m. Eastern Time on Friday, April 27, 2018.

We now weight long - term financial results at 80 % and ESG performance at 20 %.

Harmonic will host a conference call to discuss its financial results at 2:00 p.m. PT (5:00 p.m. ET) on Monday, April 30, 2018.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

You might be surprised that this point is only listed at number four on the list, but it is important to recognize the reality that any business is driven and guided by the financial results.

Specifically, Defendants made false and / or misleading statements and / or failed to disclose that: (i) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius» acquisition of Akorn; (ii) the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Akorn shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 26, 2018, to discuss these financial results and provide an update on the company.

On Thursday, April 26, 2018, David D. Petratis, chairman, president and CEO, and Patrick Shannon, senior vice president and chief financial officer, will conduct a conference call for analysts and investors, beginning at 8 a.m. ET, to review the company's results.

United rejected the criticism, saying Munoz was «focused on getting out on the front line to enhance the customer and employee experience at United, and the results are evident in our improved operational and financial performance.»

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

This came about because officials at the New York State Department of Financial Services (NYDFS) realized that an egregious financial sector hack - one that results in catastrophic consequences - remains highly probable, if not Financial Services (NYDFS) realized that an egregious financial sector hack - one that results in catastrophic consequences - remains highly probable, if not financial sector hack - one that results in catastrophic consequences - remains highly probable, if not imminent.

DUBLIN, April 19, 2018 / PRNewswire / — Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 26, 2018, to discuss the company's first quarter 2018 financial results.

Cirrus Logic will host a live Q&A session at 5 p.m. EDT today to answer questions related to its financial results and business outlook.

In fact, hard - driving, «results - at - all - costs» executives actually hurt the bottom line, while self - aware leaders with strong interpersonal skills deliver better financial performance.

For more details on T - Mobile's Q1 2018 financial results, including the Investor Factbook with detailed financial tables and reconciliations of certain historical non-GAAP measures disclosed in this release to the most comparable measures under GAAP, please visit T - Mobile US, Inc.'s Investor Relations website at http://investor.t-mobile.com.

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.

The trend follows the financial results seen at major telecommunications providers like AT&T (t) and Verizon (vz), which have seen their revenue from landline phones sliding precipitously while wireless phone revenue has boomed — at least until the past year or so.

A conference call will be held today at 2:00 p.m. Pacific Time to discuss the March quarter financial results and management's outlook for the June quarter.

Last month, Valeant announced it had to restate its financial results for 2014 and 2015 after discovering that about US$ 58 million of sales were recognized at the wrong time.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Humana will host a conference call at 9:00 a.m. eastern time today to discuss its financial results for the quarter and the company's expectations for future earnings.

EPS numbers usually are the first thing investors and the media look for in a business's results — and whether the number beat expectations set by industry and sell - side research analysts at financial firms.

Below we present a handful of examples of companies whose financial results (or at least isolated portions of them) will look radically different under IFRS.

On Thursday, central bank advisor Sheng Songcheng said at a finance forum in Beijing that he expects China's financial deleveraging to be less forceful next year as it has already achieved obvious results, Reuters reported.

David Littell, retirement income program director at The American College, said he expected to see gaps in the financial knowledge of the survey respondents, but even so, the results to the 38 questions were dismaying.

Its sales continued falling at double - digit rates in 2014, and its financial results came in even lower than analysts» expectations.

A dedicated partner and results - driven executive, Paul Roman has spent more than a decade at American Express Canada as a trusted advisor to companies coast to coast, helping them solve their financial challenges, attract new customers, and grow their businesses.

BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30 pm ET

Michael J. Mauboussin, head of global financial strategies at Credit Suisse, explores what results in success.

Following the announcement, Cytokinetics» senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

The results apparently impressed William F. Campbell, 55, a financial adviser who had recently relocated to a shoreline home at Lighthouse Point near Fort Lauderdale.

«The results over the past two and a half years clearly demonstrate that Starbucks at - home coffee portfolio is significantly healthier than it was before we assumed direct control from Kraft in 2011,» Troy Alstead, chief financial officer for Starbucks, said in a statement.

CARLSBAD, Calif., April 24, 2018 / PRNewswire / — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, May 4 at 11:30 a.m. Eastern Time to discuss its first quarter 2018 financial results and report on pipeline and business progress.

It is unclear when Twitter will make its financial results public to potential investors, nor when it plans to actually sell its shares or at what valuation.

But instead of enjoying the profitability that could result from such a classic strategy, Bezos kept moving into industry after industry, often at great and seemingly foolish financial cost.

We will host an investor conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 24, 2018, to review financial results for the first quarter ended March 31, 2018.

Despite the potential risks of «sleeping with the enemy,» it's easy to see the appeal of the Amazon deal for Sears: the partnership marks «the broadest distribution of Kenmore,» Sears said, and comes at a time of abysmal financial results for Sears.

«We're at a very important point with the company and its perception,» said one shareholder into the microphone, noting the disappointment felt by investors after the excitement of the BlackBerry 10 launch quickly dissipated when financial results were posted.

At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the first quarter 2018 and provide a general business update.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Gannett waited until Tribune released its annual financial filings in March, in order to get the best - possible public view of its deteriorating financials (a look that may have been clouded by the serial misadventures of Tribune financial irregularities, disclosed here (POLITICO: «Fixing the financials at Tribune Publishing»), and which resulted in the firing of the TribPub chief financial officer).

«Leveling up your finances — and adding commas — will likely be a result of consistent, positive habits sustained over a long period of time,» says Jason Kirsch, Certified Financial Planner at Marcum Financial Services LLP in Chicago.

The pro forma information set forth in this News Release should not be considered to be what the actual financial position or other results of operations would have necessarily been had Loblaw and Shoppers Drug Mart operated as a single combined company as, at, or for the periods stated.

The Company will host a conference call at 8:00 a.m., Eastern Time on April 19, 2018 to discuss its financial results as well as business developments affecting the Company.